Is it reasonable to extrapolate data from Glioblastoma and discuss Tumor Treating Fields in patients with Grade 4, IDH Mutant, astrocytomas?

While more than 90% of Grade 4 gliomas are IDH wildtype tumors (GBMs), this question does come up occasionally. Since I have no personal experience with TTF, I asked my collaborator Chirag Patel, MD, a neuro-oncologist at MDACC who regularly uses TTF in his patients, to provide his opinion. So pleas...

There is limited data on using TTF in IDH-mutated tumors. There were a total of 25 patients who had known IDH mutations with 19 receiving TTF vs 6 TMZ alone on EF 14 trial. This is too small to generate any subgroup analysis. There are case reports of patients with IDH mutations receiving TTF, one w...